Roche

21. Rozlytrek

Rozlytrek entered the market with a bang, snagging green lights in two indications—and putting Bayer on notice. The Roche drug went right up against the German drugmaker’s Vitrakvi in tough-to-treat NTRK fusion-positive tumors.